Stock Research for ARFXF

ARFXF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ARFXF Stock Chart & Research Data

The ARFXF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARFXF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARFXF Due diligence Resources & Stock Charts

The ARFXF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARFXF Detailed Price Forecast - CNN Money CNN View ARFXF Detailed Summary - Google Finance
Yahoo View ARFXF Detailed Summary - Yahoo! Finance Zacks View ARFXF Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ARFXF Trends & Analysis - Trade-Ideas Barrons View ARFXF Major Holders - Barrons
NASDAQ View ARFXF Call Transcripts - NASDAQ Seeking View ARFXF Breaking News & Analysis - Seeking Alpha
Spotlight View ARFXF Annual Report - CompanySpotlight.com OTC Report View ARFXF OTC Short Report - OTCShortReport.com
TradeKing View ARFXF Fundamentals - TradeKing Charts View ARFXF SEC Filings - Bar Chart
WSJ View Historical Prices for ARFXF - The WSJ Morningstar View Performance/Total Return for ARFXF - Morningstar
MarketWatch View the Analyst Estimates for ARFXF - MarketWatch CNBC View the Earnings History for ARFXF - CNBC
StockMarketWatch View the ARFXF Earnings - StockMarketWatch MacroAxis View ARFXF Buy or Sell Recommendations - MacroAxis
Bullish View the ARFXF Bullish Patterns - American Bulls Short Pains View ARFXF Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ARFXF Stock Mentions - StockTwits PennyStocks View ARFXF Stock Mentions - PennyStockTweets
Twitter View ARFXF Stock Mentions - Twitter Invest Hub View ARFXF Investment Forum News - Investor Hub
Yahoo View ARFXF Stock Mentions - Yahoo! Message Board Seeking Alpha View ARFXF Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ARFXF - SECform4.com Insider Cow View Insider Transactions for ARFXF - Insider Cow
CNBC View ARFXF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARFXF - OTC Markets
Yahoo View Insider Transactions for ARFXF - Yahoo! Finance NASDAQ View Institutional Holdings for ARFXF - NASDAQ


Stock Charts

FinViz View ARFXF Stock Insight & Charts - FinViz.com StockCharts View ARFXF Investment Charts - StockCharts.com
BarChart View ARFXF Stock Overview & Charts - BarChart Trading View View ARFXF User Generated Charts - Trading View


Latest Financial News for ARFXF

ProMIS Neurosciences Announces First Quarter 2018 Results
Posted on Friday May 11, 2018

TORONTO and CAMBRIDGE, MA , May 11, 2018 /CNW/ - ProMIS Neurosciences Inc. ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2018 . "We are very pleased with continued progress at ProMIS", said Executive Chairman Eugene Williams . "Successful closing of our recent private placement allows a cash runway into the second half of 2019.


ProMIS Neurosciences Closes $7.2 Million Private Placement
Posted on Tuesday May 01, 2018

TORONTO and CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (OTCQB:ARFXF) is pleased to announce that it closed yesterday a private placement of 19,306,668 Units ...


ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer’s Disease
Posted on Tuesday April 10, 2018

TORONTO and CAMBRIDGE, Mass., April 10, 2018-- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today ...


ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing
Posted on Tuesday April 03, 2018

TORONTO and CAMBRIDGE, Mass., April 03, 2018-- ProMIS Neurosciences, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the appointment ...


Enter a stock symbol to view the stock details.